Diabetes management in maternally inherited diabetes and deafness ( MIDD ): A review and a proposed treatment algorithm
Diabetes, Obesity and Metabolism · 2026-02 · 28 (2) · 826-839
DOI: 10.1111/dom.70240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.10.2025. Verfasst von Ahsen Chaudhry und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Clinician Investigator Program, University of British Columbia, Vancouver, British Columbia, Canad…. Hauptthemen laut MEDLINE: Deafness, Mitochondrial Diseases, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Breakthrough T1D Canada, University of British Columbia Clinician Investigator Program.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and moderate β‐cell heteroplasmy for m.3243A>G and to be driven by oxidative stress as a major pathophysiologic mechanism. There are no randomised trials specifically on the management of MIDD. An approach to MIDD informed by its pathophysiology could optimise management and be a framework for future trials. In this narrative review, we discuss the effects of existing anti‐hyperglycaemic medications on oxidative stress, mitochondrial function, and cardiorenal protection. We also review the published case reports and series on the management of diabetes associated with MIDD, and the safety of insulin and non‐insulin medications in MIDD. We found that glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors have favourable properties in addressing oxidative stress and mitochondrial function. They also harbour cardiorenal protection properties independent from their effect on glucose control that are fully relevant in MIDD, making them ideal candidates as first‐line agents for the management of MIDD. Accordingly, we share our perspective on a disease‐specific algorithm for the management of MIDD diabetes that could delay or prevent the development of cardiovascular and renal complications associated with this mitochondrial disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Medicine, Clinician Investigator Program, University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Endocrinology, Department of Pediatrics, British Columbia Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Ahsen Chaudhry, David M Thompson, Jean-Pierre Chanoine
Förderung
- Breakthrough T1D Canada
- University of British Columbia Clinician Investigator Program
Zitieren
APA
Chaudhry, A., Thompson, D. M., & Chanoine, J. P. (2026). Diabetes management in maternally inherited diabetes and deafness ( MIDD ): A review and a proposed treatment algorithm. Diabetes, Obesity and Metabolism, 28(2), 826-839. https://doi.org/10.1111/dom.70240
Vancouver
Chaudhry A, Thompson DM, Chanoine JP. Diabetes management in maternally inherited diabetes and deafness ( MIDD ): A review and a proposed treatment algorithm. Diabetes, Obesity and Metabolism. 2026;28(2):826-839. doi:10.1111/dom.70240
BibTeX
@article{Chaudhry2026,
author = {Chaudhry, Ahsen and Thompson, David M and Chanoine, Jean-Pierre},
title = {Diabetes management in maternally inherited diabetes and deafness ( MIDD ): A review and a proposed treatment algorithm},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {2},
pages = {826--839},
doi = {10.1111/dom.70240}
}
EUVIMED